Core Thesis - Tilray Brands, Inc. is positioned for growth through diversification and international expansion, with a focus on cannabis, beverage, and medical products [2][3][6] Financial Performance - Q4 revenue grew 25% year-over-year to $229.9 million, with beverage sales surpassing cannabis revenue for the first time [2] - Q3 2025 results showed revenue of $209.5 million and non-GAAP breakeven EPS, leading to a 22% intraday share price increase [6] Strategic Initiatives - The company acquired four craft breweries from Molson Coors and introduced new cannabis strains in Canada, indicating a commitment to strategic growth [3] - Tilray expanded its medical cannabis programs and obtained new cultivation and trading licenses in Germany, while launching additional products in Portugal and Canada [2] Market and Regulatory Environment - Political developments in 2024, including potential cannabis deregulation under the Trump administration, created speculation around federal reform [3][5] - Despite Florida voters rejecting a legalization amendment, there is sector-wide optimism regarding easing restrictions and potential banking access for cannabis firms [4] Investor Sentiment - A 14% post-market surge in Tilray shares followed signals from the Trump administration regarding potential cannabis reclassification, renewing investor interest [5] - The company is seen as having a compelling risk/reward profile due to a stronger revenue mix, improving balance sheet, and favorable policy sentiment [6]